肠道微生物群与基于内素的疗法之间的双向相互作用
Vincenzo Trapanese1, Annamaria Dagostino1, Maria Resilde Natale1
1Internal Medicine Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
Life (Basel, Switzerland)
|June 26, 2025
概括
新型抗糖尿病药物,比如基于因克雷的疗法,对肠道微生物群的组成产生积极影响. 这篇评论探讨了这些治疗方法如何影响肠道细菌,为肥胖和2型糖尿病 (T2DM) 提供了新的策略.
科学领域:
- 微生物学 微生物学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖,胰岛素耐药性,2型糖尿病 (T2DM) 和代谢综合征与肠道细菌多样性减少 (肠道失生症) 有关.
- 新兴的抗糖尿病药物在有利于改变肠道微生物群组成方面表现有前途.
研究的目的:
- 审查基于隐素的疗法,包括DPP-4抑制剂和GLP-1/GIP受体激动剂,对小鼠和人类肠道微生物群的影响.
- 为了阐明隐形轴与肠道微生物组成之间的复杂,双向相互作用.
主要方法:
- 关于研究基于因克雷的疗法及其对肠道微生物群的影响的文献综述.
- 对临床前 (小鼠) 和临床 (人类) 试验对象的影响分析.
主要成果:
- 基于因克雷的疗法对肠道微生物群组成和细菌菌群产生多方面的影响.
- 肠道微生物代谢物在调节肠内分泌细胞活性和荷尔蒙分泌方面发挥着重要作用.
结论:
- 隐形轴参与调节微生物组成,这表明了新的预防策略的潜力.
- 这些发现突出了通过微生物群调节来治疗肥胖和T2DM的潜在个性化治疗点.
相关概念视频
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Anatomy of the Intestines
74.2K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
74.2K


